arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Acurx Pharmaceuticals, Inc.

ACXP

$1.37 0.00 (0.00%) at close

6 Visible periods

15 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Acurx Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -121.3% ↗

FCF / Share $-4.53 ↗

Trailing P/E —

Price / Book 0.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-7.97M

↑ +43.5% —

FCF / Share Free cash flow per share

$-4.53

↑ +64.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	69.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	24.1% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-2.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	24.8% Good Good Year-over-year change in earnings per share Optimal: > 10%	-101.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	43.5% Excellent ↑ Excellent Improving Year-over-year change in net income	3.3% Caution ↑ Caution Improving Year-over-year change in net income	-20.5% Weak ↑ Weak Improving Year-over-year change in net income	5.1% Fair Fair Year-over-year change in net income	-177.1% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	64.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	16.9% Good ↑ Good Improving Year-over-year change in free cash flow	-10.9% Weak ↑ Weak Improving Year-over-year change in free cash flow	-18.7% Weak Weak Year-over-year change in free cash flow	-8.5% Weak Weak Year-over-year change in free cash flow	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.39x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-121.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-1813.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-105.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-366.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-151.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1108%)	—	—	-165.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1202%)	-102.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-785%)	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-5.32	$-17.45	$-23.00	$-22.40	$-29.80	$-14.80
Free Cash Flow per Share (USD)	$-4.53	$-12.85	$-15.47	$-13.95	$-11.75	$-10.83
Book Value per Share (USD)	$2.24	$0.72	$6.45	$12.58	$24.30	—
Tangible Book Value per Share (USD)	$2.24	$0.72	$6.45	$12.58	$24.30	—
Basic Weighted Avg Shares (shares)	1.50M	808,168	633,579	540,821	426,794	309,544

🏦 How resilient is the balance sheet? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Total Equity (USD)	$5.27M	$615.12K	$4.67M	$7.32M	$12.41M	—

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Income, GAAP (USD)	$-7.97M	$-14.10M	$-14.58M	$-12.09M	$-12.75M	$-4.60M
Operating Cash Flow (USD)	$-6.79M	$-10.38M	$-9.80M	$-7.54M	$-5.01M	$-3.35M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 26 quarters

Acurx Pharmaceuticals, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ACXP with peers